FUDANZHANGJIANG - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever as to the accuracy or completeness of the whole or any part of this announcement. assumes no liability for any loss arising from or arising from reliance on such content.

Overseas regulatory announcement

This announcement is made by Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. (the "Company") under the Hong Kong Stock Exchange Ltd. Securities Listing Rules 13.10(B).

This is to set forth the "Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. II" published by the company on the website of the Shanghai Stock Exchange. Special Report on Deductions of Operating Income in 2025" is for reference only. This document and its disclosures are based on the It is prepared and published in accordance with national laws and regulations and relevant domestic regulatory requirements.

By order of the board of directors

Zhao Dajun Chairman

As at the date of this announcement, the Board of Directors includes the following individuals:

Mr. Zhao Dajun (Executive Director)

Ms. Xue Yan (Executive Director)

Mr. Shen Bo (Non-executive Director) Ms. Yu Xiaoyang (Non-executive Director)

Mr. Wang Hongguang (Independent Non-executive Director) Mr. Lam Siu Wing (Independent Non-executive Director)

Mr. Xu Peilong (Independent Non-executive Director)

Ms. Qu Yanan (Employee Director)

Shanghai, China

March 30, 2026 *Identification only